PDF(Pubmed)
Abstract：
BACKGROUND: Autoimmunity has been associated with different types of cancer, including hematological malignancies like lymphomas, and solid tumors. Additionally, the potential role of medication-induced immunosuppression should be considered.
OBJECTIVE: Our study aimed to investigate the relationship between autoimmunity and the development of cancer, as well as the impact of immunosuppressive drugs on increasing cancer risk.
METHODS: The study sample was composed of patients who developed cancer after the administration of biological agents for the treatment of autoimmune disorders. Selected patients were treated in our hospital between 1st January 2011 and 31st December 2021 and followed up in internal medicine, gastroenterology, or dermatology consult. From 434 patients with autoimmune diseases using biological agents, only 20 developed cancer, which was our final study sample. The data analysis was performed using the IQVIR package version 2.0.2 (IQVIA, Durham, NC). A p-value of <0.05 was considered statistically significant.
RESULTS: We found a significant correlation between long-term corticosteroid therapy and an increased risk of cancer. However, the effect of biological therapies on cancer risk was not statistically significant. It\'s worth noting that our sample size was small, so we cannot extrapolate these findings.
CONCLUSIONS: Physicians need to be aware that treating autoimmune diseases with immunosuppressive therapies may contribute to the development of cancer. Further research is needed to determine the impact of such treatments on cancer prognosis.
OBJECTIVE: Our study aimed to investigate the relationship between autoimmunity and the development of cancer, as well as the impact of immunosuppressive drugs on increasing cancer risk.
METHODS: The study sample was composed of patients who developed cancer after the administration of biological agents for the treatment of autoimmune disorders. Selected patients were treated in our hospital between 1st January 2011 and 31st December 2021 and followed up in internal medicine, gastroenterology, or dermatology consult. From 434 patients with autoimmune diseases using biological agents, only 20 developed cancer, which was our final study sample. The data analysis was performed using the IQVIR package version 2.0.2 (IQVIA, Durham, NC). A p-value of <0.05 was considered statistically significant.
RESULTS: We found a significant correlation between long-term corticosteroid therapy and an increased risk of cancer. However, the effect of biological therapies on cancer risk was not statistically significant. It\'s worth noting that our sample size was small, so we cannot extrapolate these findings.
CONCLUSIONS: Physicians need to be aware that treating autoimmune diseases with immunosuppressive therapies may contribute to the development of cancer. Further research is needed to determine the impact of such treatments on cancer prognosis.
摘要：
背景：自身免疫与不同类型的癌症有关，包括恶性血液病如淋巴瘤,和实体瘤。此外,应考虑药物诱导的免疫抑制的潜在作用.
目的：我们的研究旨在探讨自身免疫与癌症发展之间的关系，以及免疫抑制药物对增加癌症风险的影响。
方法：研究样本由在施用治疗自身免疫性疾病的生物制剂后发展为癌症的患者组成。所选患者于2011年1月1日至2021年12月31日期间在我院接受治疗，并在内科进行随访，胃肠病学,或皮肤科咨询。从使用生物制剂的434例自身免疫性疾病患者中，只有20人患上癌症，这是我们最后的研究样本.数据分析使用IQVIR软件包版本2.0.2（IQVIA，达勒姆,NC）。P值<0.05被认为是统计学上显著的。
结果：我们发现长期皮质类固醇治疗与癌症风险增加之间存在显著相关性。然而,生物疗法对癌症风险的影响无统计学意义.值得注意的是我们的样本量很小,所以我们无法推断这些发现。
结论：医生需要意识到用免疫抑制疗法治疗自身免疫性疾病可能有助于癌症的发展。需要进一步的研究来确定这种治疗对癌症预后的影响。
目的：我们的研究旨在探讨自身免疫与癌症发展之间的关系，以及免疫抑制药物对增加癌症风险的影响。
方法：研究样本由在施用治疗自身免疫性疾病的生物制剂后发展为癌症的患者组成。所选患者于2011年1月1日至2021年12月31日期间在我院接受治疗，并在内科进行随访，胃肠病学,或皮肤科咨询。从使用生物制剂的434例自身免疫性疾病患者中，只有20人患上癌症，这是我们最后的研究样本.数据分析使用IQVIR软件包版本2.0.2（IQVIA，达勒姆,NC）。P值<0.05被认为是统计学上显著的。
结果：我们发现长期皮质类固醇治疗与癌症风险增加之间存在显著相关性。然而,生物疗法对癌症风险的影响无统计学意义.值得注意的是我们的样本量很小,所以我们无法推断这些发现。
结论：医生需要意识到用免疫抑制疗法治疗自身免疫性疾病可能有助于癌症的发展。需要进一步的研究来确定这种治疗对癌症预后的影响。
